UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)

Diabetes care, 2014-11, Vol.37 (11), p.2926-2933

2014

Volltextzugriff (PDF)

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

Diabetes care, 2014-08, Vol.37 (8), p.2159-2167

2014

Volltextzugriff (PDF)

Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus

Postgraduate medicine, 2017-01, Vol.129 (1), p.159-168

2017

Volltextzugriff (PDF)

Efficacy and safety of MYL‐1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study

Diabetes, obesity & metabolism, 2020-03, Vol.22 (3), p.365-372

2020

Volltextzugriff (PDF)

Efficacy and safety of MYL‐1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study

Diabetes, obesity & metabolism, 2018-08, Vol.20 (8), p.1944-1950

2018

Volltextzugriff (PDF)

Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study

Diabetes technology & therapeutics, 2021-04, Vol.23 (4), p.286-292

2021

Volltextzugriff (PDF)

Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study

Diabetes, obesity & metabolism, 2019-01, Vol.21 (1), p.129-135

2019

Volltextzugriff (PDF)

Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules

Thyroid (New York, N.Y.), 2014-10, Vol.24 (10), p.1479-1487

2014

Volltextzugriff (PDF)

Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2022-11, Vol.36 (6), p.761-772

2022

Volltextzugriff (PDF)

Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier

Thyroid (New York, N.Y.), 2022-09, Vol.32 (9), p.1069-1076

2022

Volltextzugriff (PDF)

Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin

Diabetes, obesity & metabolism, 2019-06, Vol.21 (6), p.1506-1512

2019

Volltextzugriff (PDF)

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

Diabetes care, 2013-03, Vol.36 (3), p.522-528

2013

Volltextzugriff (PDF)

Extreme hypertriglyceridemia: Genetic diversity, pancreatitis, pregnancy, and prevalence

Journal of clinical lipidology, 2019-01, Vol.13 (1), p.89-99

2019

Volltextzugriff (PDF)

Professional continuous glucose monitoring in clinical practice 2010

Journal of diabetes science and technology, 2010-03, Vol.4 (2), p.440-456

Blevins, Thomas C

2010

Volltextzugriff (PDF)

LONG-TERM NONOPERATIVE RATE OF THYROID NODULES WITH BENIGN RESULTS ON THE AFIRMA GENE EXPRESSION CLASSIFIER

Endocrine practice, 2016-06, Vol.22 (6), p.666-672

2016

Volltextzugriff (PDF)

Statement by the American Association of Clinical Endocrinologists Consensus Panel on continuous glucose monitoring

Endocrine practice, 2010-09, Vol.16 (5), p.730-745

2010

Volltextzugriff (PDF)

Anatabine Supplementation Decreases Thyroglobulin Antibodies in Patients With Chronic Lymphocytic Autoimmune (Hashimoto's) Thyroiditis: A Randomized Controlled Clinical Trial

The journal of clinical endocrinology and metabolism, 2014-01, Vol.99 (1), p.E137-E142

2014

Volltextzugriff (PDF)

Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin

Expert opinion on drug safety, 2015-05, Vol.14 (5), p.789-793

Blevins, Thomas

2015

Volltextzugriff (PDF)

Value and Utility of Self-Monitoring of Blood Glucose in Non-Insulin-Treated Patients With Type 2 Diabetes Mellitus

Postgraduate medicine, 2013-05, Vol.125 (3), p.191-204

Blevins, Thomas

2013

Volltextzugriff (PDF)

American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus

Endocrine practice, 2021-06, Vol.27 (6), p.505-537

2021

Volltextzugriff (PDF)

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

The New England journal of medicine, 2023-09, Vol.389 (10), p.877-888

2023

Volltextzugriff (PDF)

Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes

Journal of diabetes, 2016-01, Vol.8 (1), p.166-169

2016

Volltextzugriff (PDF)

Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D

Diabetes care, 2020-12, Vol.43 (12), p.2991-2998

2020

Volltextzugriff (PDF)

Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin: Evaluation of Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014;16:147-158

Expert opinion on drug safety, 2015-05, Vol.14 (5), p.789-793

Blevins, Thomas

2015

Volltextzugriff (PDF)

Hot Topics in Primary Care: Demystifying the Differences: Follow-on Biologics, Biosimilars, and Generics

The Journal of family practice, 2017-04, Vol.66 (4 Suppl), p.S22-S27

2017

Volltextzugriff (PDF)

1 – 25 von 248

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(218)
Mit Volltextzugriff
(191)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(148)
Life Sciences & Biomedicine
(133)
Humans
(95)
Female
(57)
Male
(57)
Endocrinology & Metabolism
(37)
Diabetes
(36)
Adult
(34)
Middle Aged
(29)
Insulin
(27)
Aged
(23)
Biological And Medical Sciences
(23)
Adolescent
(20)
Medical Sciences
(20)
Hypoglycemia
(19)
Treatment Outcome
(19)
Diabetes Mellitus
(17)
Hypoglycemic Agents - Therapeutic Use
(16)
Animals
(15)
Diabetes Mellitus, Type 2 - Drug Therapy
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus

Efficacy and safety of MYL‐1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study

Efficacy and safety of MYL‐1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study

Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study

Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study

Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules

Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study

Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier

Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

Extreme hypertriglyceridemia: Genetic diversity, pancreatitis, pregnancy, and prevalence

Professional continuous glucose monitoring in clinical practice 2010

LONG-TERM NONOPERATIVE RATE OF THYROID NODULES WITH BENIGN RESULTS ON THE AFIRMA GENE EXPRESSION CLASSIFIER

Statement by the American Association of Clinical Endocrinologists Consensus Panel on continuous glucose monitoring

Anatabine Supplementation Decreases Thyroglobulin Antibodies in Patients With Chronic Lymphocytic Autoimmune (Hashimoto's) Thyroiditis: A Randomized Controlled Clinical Trial

Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin

Value and Utility of Self-Monitoring of Blood Glucose in Non-Insulin-Treated Patients With Type 2 Diabetes Mellitus

American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes

Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D

Hot Topics in Primary Care: Demystifying the Differences: Follow-on Biologics, Biosimilars, and Generics

Suchergebnisse filtern